Search

Your search keyword '"V. Dheenadhayalan"' showing total 25 results

Search Constraints

Start Over You searched for: Author "V. Dheenadhayalan" Remove constraint Author: "V. Dheenadhayalan" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
25 results on '"V. Dheenadhayalan"'

Search Results

1. Mycobacterium bovisBCG Scar Status and HLA Class II Alleles Influence Purified Protein Derivative-Specific T-Cell Receptor Vβ Expression in Pulmonary Tuberculosis Patients from Southern India

2. Association of Interleukin-10 Cytokine Expression Status with HLA Non-DRB1*02 andMycobacterium bovisBCG Scar-Negative Status in South Indian Pulmonary Tuberculosis Patients

3. Associations of HLA-DRB1, DQB1 and DPB1 alleles with pulmonary tuberculosis in south India

4. Major histocompatibility complex restriction in tuberculosis susceptibility

5. Historical evaluation of the in vivo adventitious virus test and its potential for replacement with next generation sequencing (NGS).

6. Corrigendum: T-cell activation is an immune correlate of risk in BCG vaccinated infants.

7. Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial.

8. T-cell activation is an immune correlate of risk in BCG vaccinated infants.

9. A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.

10. A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants.

11. The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3).

12. A nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402/Ad35 vaccine: Evidence for transient t cell responses in peripheral blood and robust sustained responses in the lungs.

13. Stabilizing formulations for inhalable powders of an adenovirus 35-vectored tuberculosis (TB) vaccine (AERAS-402).

14. Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen.

15. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis.

16. The safety of post-exposure vaccination of mice infected with Mycobacterium tuberculosis.

17. Mycobacterium bovis BCG immunization induces protective immunity against nine different Mycobacterium tuberculosis strains in mice.

18. Variable expression patterns of Mycobacterium tuberculosis PE_PGRS genes: evidence that PE_PGRS16 and PE_PGRS26 are inversely regulated in vivo.

19. A PE protein expressed by Mycobacterium avium is an effective T-cell immunogen.

20. Expression of the PE_PGRS 33 protein in Mycobacterium smegmatis triggers necrosis in macrophages and enhanced mycobacterial survival.

21. The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis.

22. Mycobacterium bovis BCG scar status and HLA class II alleles influence purified protein derivative-specific T-cell receptor V beta expression in pulmonary tuberculosis patients from southern India.

23. Cloning and characterization of the genes coding for antigen 85A, 85B and 85C of Mycobacterium avium subsp. paratuberculosis.

24. Association of interleukin-10 cytokine expression status with HLA non-DRB1*02 and Mycobacterium bovis BCG scar-negative status in south Indian pulmonary tuberculosis patients.

25. Associations of HLA-DRB1, DQB1 and DPB1 alleles with pulmonary tuberculosis in south India.

Catalog

Books, media, physical & digital resources